Protagenic gets FDA green light to submit IND for anxiety drug
The FDA raised no objections to Protagenic's plan for testing PT00114 for generalized anxiety disorder, with submission targeted for late 2026. The biotech shares advanced to a 'Clear Path' designation, significantly de-risking its next clinical phase.
View filing at SEC.gov →